SCHEMBL653329

SCHEMBL653329

CC1(O)CCN(Cc2ccccc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 2/20 0.67
POLB P06746 2/20 0.65
SIGMAR1 Q99720 3/20 0.61
CYP3A4 P08684 1/20 0.61
HSD17B10 Q99714 1/20 0.61
CCR3 P51677 1/20 0.59
CYP2D6 P10635 1/20 0.58
MC4R P32245 1/20 0.56
MEN1 O00255 1/20 0.56
ALDH1A1 P00352 1/20 0.56
CYP2C9 P11712 1/20 0.56
TSHR P16473 1/20 0.56
CYP2C19 P33261 1/20 0.56
KMT2A Q03164 1/20 0.56
HIF1A Q16665 1/20 0.56
LMNA P02545 1/20 0.55
OPRM1 P35372 2/20 0.53
OPRK1 P41145 1/20 0.53
ACHE P22303 1/20 0.53
CHRM2 P08172 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19613477 0.89 OPRL1 (0.58) OPRL1POLBSIGMAR1CYP3A4HSD17B10
SCHEMBL951796 0.89 OPRL1 (0.58) OPRL1POLBSIGMAR1CYP3A4HSD17B10
Hydrochloric Acid SCHEMBL6615899 0.88 POLB (0.59) OPRL1POLBSIGMAR1CYP3A4HSD17B10
SCHEMBL12013906 0.85 SIGMAR1 (0.65) OPRL1POLBSIGMAR1CYP3A4HSD17B10
SCHEMBL28548988 0.85 OPRL1 (0.71) OPRL1POLBSIGMAR1CYP3A4HSD17B10
SCHEMBL16084085 0.85 OPRL1 (0.54) OPRL1POLBSIGMAR1CYP3A4HSD17B10
Ammonia Solution, Strong SCHEMBL14735243 0.83 SIGMAR1 (0.63) OPRL1POLBSIGMAR1CYP3A4HSD17B10
SCHEMBL22121643 0.82 OPRL1 (0.46) OPRL1POLBCYP3A4HSD17B10CCR3
SCHEMBL1269135 0.82 OPRL1 (0.58) OPRL1POLBSIGMAR1CYP3A4HSD17B10
SCHEMBL3859171 0.82 SIGMAR1 (0.49) OPRL1POLBSIGMAR1CCR3HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 US disclosed
US-12213970-B2 Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-02-04 US disclosed
WO-2025010314-A1 UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-01-09 WO disclosed
CN-112955214-B Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof 勃林格殷格翰国际有限公司 2024-05-07 CN disclosed
EP-3873599-B1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2023-09-27 EP disclosed
EP-3873599-B1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2023-09-27 EP disclosed
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-5534525-A Lactam derivatives ZENECA LIMITED (GB) 1996-07-09 US disclosed
US-5498618-A ANTAGONISM OF 5-HT2 JANSSEN PHARMACEUTICA N.V. (BE) 1996-03-12 US disclosed
WO-1995012577-A1 NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA ZENECA LIMITED (GB) 1995-05-11 WO disclosed
EP-0650475-A1 4-AMINO-N --(4-METHYL-4-PIPERIDINYL)-2-METHOXYBENZAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1995-05-03 EP disclosed
EP-0625507-A2 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO., LTD. (JP) 1994-11-23 EP disclosed
WO-1994022829-A2 DIHYDROPYRIDINES AND NEW USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1994-10-13 WO disclosed
WO-1994002462-A1 4-AMINO-N^_-(4-METHYL-4-PIPERIDINYL)-2-METHOXYBENZAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1994-02-03 WO disclosed
EP-0106276-B1 1,4-DIHYDROPYRIDINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 1988-10-26 EP disclosed
US-4639522-A HYPOTENSIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 1987-01-27 US disclosed
EP-0106276-A2 1,4-Dihydropyridine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1984-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 OPRL1 2927/4885POLB 3436/4885SIGMAR1 4335/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 OPRL1 5/4885POLB 4468/4885SIGMAR1 127/4885
US-12213970-B2 Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof ARSA, SULT1A1, SULT2A1 OPRL1 2133/4885POLB 4024/4885SIGMAR1 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.